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Aims Very few data exist on the occurrence of acute kidney injury (AKI) associated with transcatheter aortic valve implan-
tation (TAVI). The objectives of the present study were (i) to determine the incidence, predictive factors, and prog-
nostic value of AKI following TAVI, and (ii) to compare the occurrence of AKI in TAVI vs. surgical aortic valve
replacement (SAVR) in patients with pre-procedural chronic kidney disease (CKD).
Methods
and results
Atotalof213patients(meanage82+8years)undergoingTAVIforthetreatmentofsevereaorticstenosiswereincluded
inthestudy.Acutekidneyinjurywasdeﬁnedasareductionof .25%inestimatedglomerularﬁltrationrate(eGFR)within
48 h following the procedure or the need for haemodialysis during index hospitalization. Those patients with pre-pro-
cedural CKD (eGFR ,60 mL/min/1.73 m
2, n ¼ 119) were compared with 104 contemporary patients with CKD who
underwent isolated SAVR. The incidence ofAKI following TAVI was11.7%, with1.4% ofthepatients requiring haemodia-
lysis. Predictive factorsofAKI were hypertension(OR:4.66;95% CI: 1.04–20.87),chronic obstructive pulmonary disease
(OR: 2.64, 95% CI: 1.10–6.36), and peri-operative blood transfusion (OR: 3.47, 95% CI: 1.30–9.29). Twenty-one patients
(9.8%)diedduringindexhospitalization,andthelogisticEuroSCORE(OR:1.03foreachincreaseof1%;95%CI:1.01–1.06)
and occurrence of AKI (OR: 4.14, 95% CI: 1.42–12.13) were identiﬁed as independent predictors of postoperative mor-
tality. Patients with CKD who underwent TAVI were older, had a higher logistic EuroSCORE and lower pre-procedural
eGFR values compared with those who underwent SAVR (P , 0.0001 for all). The incidence of AKI was lower
(P ¼ 0.001; P ¼ 0.014 after propensity score adjustment) in CKD patients who underwent TAVI (9.2%, need for haemo-
dialysis: 2.5%) compared with those who underwent SAVR (25.9%, need for haemodialysis: 8.7%).
Conclusion Acute kidney injury occurred in 11.7% of the patients following TAVI and was associated with a greater than four-fold
increase in the risk of postoperative mortality. Hypertension, chronic obstructive pulmonary disease, and blood trans-
fusion were predictive factors of AKI. In those patients with pre-procedural CKD, TAVI was associated with a signiﬁ-
cant reduction of AKI compared with SAVR.
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Acute kidney injury (AKI) is one of the most serious complications
following cardiac surgery, with an incidence varying between 1 and
30% depending on the deﬁnition of AKI and baseline characteristics
of the study population.
1 Several studies have shown that the
occurrence of AKI after cardiac surgery is an independent predic-
tor of in-hospital, mid- and long-term mortality, with a two- to
three-fold increase in the risk of death in those patients presenting
AKI following the intervention.
1–4 Surgical aortic valve replace-
ment (SAVR) is the gold standard for the treatment of sympto-
matic severe aortic stenosis (AS), and transcatheter aortic valve
implantation (TAVI) has emerged as an alternative treatment for
those patients considered at very high or prohibitive surgical
risk.
5–8 Patients undergoing TAVI nowadays are thus commonly
very old and have a high prevalence of chronic kidney disease
(CKD). In fact, trying to avoid potential deterioration of renal func-
tion in patients with CKD has become an important argument for
choosing TAVI rather than SAVR in those cases. However, very few
data exist on the occurrence and prognosis of AKI following TAVI,
9
and no studies have as yet determined whether a TAVI strategy is
associated with a lower incidence of AKI compared with SAVR.
TAVI procedures involve the administration of contrast media,
the systematic occurrence of short periods of extreme hypoten-
sion (rapid pacing, balloon valvuloplasty, and valve deployment),
and the manipulation of large catheters in the aorta of patients
with a high prevalence of diffuse atherosclerosis with the risk of
cholesterol embolization, all of them are potential risk factors
for AKI. Therefore, the objectives of this study were (i) to deter-
mine the incidence, predictive factors, and prognostic value of AKI
following TAVI, and (ii) to compare the occurrence of AKI in TAVI
vs. SAVR in the subset of patients with pre-procedural CKD.
Methods
Patients
A total of 243 patients diagnosed with symptomatic severe AS under-
went TAVI at the St Paul’s Hospital (n ¼ 188, four operators), Vancou-
ver, British Columbia, Canada, and the Quebec Heart and Lung
Institute (n ¼ 55, four operators), Quebec city, Quebec, Canada,
between January 2005 and February 2009. Patients on chronic haemo-
dialysis (n ¼ 7), those participating in the PARTNER (Placement of
AoRTic traNscathetER valve) trial (n ¼ 15), and those who died
within the 24 h precluding creatinine measurements following TAVI
(n ¼ 8) were excluded from the study, leading to a ﬁnal study popu-
lation of 213 patients. TAVI was approved for compassionate clinical
use by the Canadian Department of Health and Welfare (Ottawa,
Canada) in patients with symptomatic severe AS considered either
non-operable or very high risk surgical candidates, and all patients pro-
vided signed informed consent for the procedures. All clinical, echo-
cardiographic, procedural, and post-procedural data were
prospectively gathered. A total of 119 patients (56%) undergoing
TAVI had pre-procedural CKD [deﬁned as an estimated glomerular ﬁl-
tration rate (eGFR) ,60 mL/min/1.73 m
2]
10 and were compared with
104 consecutive patients (nine operators) with severe AS and CKD
who underwent isolated SAVR at the Quebec Heart and Lung Institute
from January 2005 to February 2009. This surgical cohort was obtained
from the Quebec Heart and Lung Institute surgical database and all
data were prospectively collected.
Transcatheter aortic valve implantation and
surgical aortic valve replacement procedures
TAVI procedures have been described in detail in previous reports.
5–8
The Cribier–Edwards or Edwards-SAPIEN valve (Edwards Lifesciences
Inc., Irvine, CA, USA) was used in all cases either by transfemoral (n ¼
111, 52%) or transapical (n ¼ 102, 48%) approach. Patients with pre-
procedural CKD received intravenous hydration before and after the
procedure, and the use of a prophylactic treatment (N-acetylcysteine,
intravenous bicarbonate) was left at the discretion of the physician per-
forming the procedure. The amount of contrast, number of rapid
pacing runs, the occurrence of any complication leading to severe
maintained hypotension, and/or the need for haemodynamic support
(aortic counterpulsation balloon and extracorporeal circulation)
were recorded. A successful procedure was deﬁned as the implan-
tation of a functioning prosthetic valve within the aortic annulus at
the end of the procedure without in-laboratory mortality. SAVR pro-
cedures were performed through mid-sternotomy, using standard sur-
gical techniques and under extracorporeal circulation.
Serum creatinine measurements and acute
kidney injury deﬁnition
All patients in both TAVI and SAVR groups had a systematic determi-
nation of serum creatinine and eGFR calculation based on the simpli-
ﬁed modiﬁcation of diet in renal disease (MDRD) formula
11 before
(,7 days) and at 48 h following the procedure. The occurrence of
AKI was deﬁned as a decrease of .25% in eGFR at 48 h following
the procedure (RIFLE criteria),
12 or the need of haemodialysis during
index hospitalization. The degree of AKI was further classiﬁed as (i)
.25% decrease in eGFR, (ii) 50–75% decrease in eGFR, and (iii)
.75% decrease in eGFR.
Statistical analysis
Qualitative variables were expressed as percentages and quantitative
variables as mean (standard deviation) or median (interquartile
range). The normality distribution for continuous data was examined
with the Shapiro–Wilk test. Comparison of numerical variables was
performed using the two-sided Student’s t-test or Wilcoxon
rank-sum test, and the chi-square or Fischer’s exact tests were used
to compare qualitative variables. A stepwise logistic regression analysis
including all variables with P-value , 0.2 in the univariate analysis was
used to determine the predictive factors of both AKI and hospital mor-
tality. The following variables were included in the model for the pre-
diction of AKI: age, hypertension, chronic obstructive pulmonary
disease, logistic EuroSCORE, procedural approach (transfemoral vs.
transapical), procedural time, contrast media volume, any complication
leading to the need of haemodynamic support, red blood cell (RBC)
transfusion, and post-procedural myocardial infarction. The variables
included in the model for the prediction of in-hospital death were:
male gender, cerebrovascular disease, peripheral vascular disease,
chronic obstructive pulmonary disease, pre-procedural serum creati-
nine, logistic EuroSCORE, left ventricular ejection fraction, pre-
procedural mean aortic gradient, pulmonary artery pressure, pro-
cedural approach, contrast media volume, RBC transfusion, number
of RBC units, post-procedural stroke, post-procedural pneumonia or
sepsis, serum creatinine and eGFR at 48 h post-procedure, and AKI.
A continuous propensity score analysis was performed to adjust for
the intergroup (TAVI vs. SAVR in patients with CKD) differences in
baseline clinical characteristics caused by the selection bias inherent
R. Bagur et al. 866to the nonrandomized nature of the study. A propensity score repre-
senting the likelihood of having TAVI as opposed to SAVR was calcu-
lated for each patient by using a logistic regression analysis that
identiﬁed variables independently associated with the type of pro-
cedure. Variables exhibiting a P-value , 0.2 in the univariate analysis
were included in the logistic regression analysis. The variables used
for the propensity score were: age, logistic EuroSCORE, congestive
heart failure, coronary artery disease, peripheral vascular disease,
and baseline eGFR. In addition, the incidence of post-procedural AKI
was further evaluated after patient matching based on pre-procedural
eGFR values between TAVI and SAVR groups. Differences were con-
sidered statistically signiﬁcant at P-values , 0.05. The data were ana-
lysed using SAS statistical software version 9.1.3 (SAS Institute Inc.,
Cary, NC, USA).
Results
Baseline clinical and echocardiographic characteristics of the study
population and the main TAVI peri-procedural characteristics are
shown in Table 1. Acute kidney injury occurred in 25 patients
(11.7%) and 3 patients (1.4%) required dialysis during index hospi-
talization. The changes in eGFR at 48 h following TAVI are shown
in Table 1 and Figure 1.
Predictive factors of acute kidney injury
Baseline and procedural characteristics of the study population
grouped according to the occurrence of AKI are shown in
Table 2. Patients who presented AKI had more frequently a
history of hypertension (92 vs. 68%, P ¼ 0.010) and chronic
obstructive pulmonary disease (52 vs. 30%, P ¼ 0.038), tended
to have a TAVI procedure performed by transapical approach
(64 vs. 46%, P ¼ 0.093) and required more frequently blood trans-
fusions during the peri-procedural period (76 vs. 45%, P ¼ 0.005).
................................................................................
................................................................................
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Table 1 Baseline, peri-procedural characteristics, and
post-procedural renal function of patients undergoing
transcatheter aortic valve implantation
Variable n 5 213
Clinical characteristics
Age (years) 82+8
Male sex 99 (47)
Diabetes 48 (23)
Hypertension 150 (70)
Congestive heart failure 115 (54)
New York Heart Association class
I–II 22 (10)
III–IV 191 (90)
Coronary artery disease 143 (67)
Cerebrovascular disease 61 (29)
Peripheral vascular disease 84 (39)
Chronic obstructive pulmonary disease 69 (32)
Serum creatinine (mg/dL) 1.24+0.5
eGFR (mL/min/1.73 m
2), median (interquartile
range)
57 (43–77)
eGFR ,60 (mL/min/1.73 m
2) 119 (56)
Haemoglobin (g/dL) 12+1.6
Logistic EuroSCORE 29.3+17.5
Echocardiographic data
Left ventricular ejection fraction 57+15
Left ventricular ejection fraction ,40% 25 (12)
Mean gradient (mmHg) 44+17
Aortic valve area (cm
2) 0.63+0.16
Pulmonary artery systolic pressure (mmHg) 50+12
Moderate to severe mitral regurgitation 72 (35)
Peri-procedural variables
Approach
Transapical 102 (48)
Transfemoral 111 (52)
Time of procedure ‘skin to skin’ (min), median
(interquartile range)
85 (50–477)
Contrast amount (cm
3)9 7 +57
Rapid pacing runs 5.4+2.1
Life-threatening arrhythmias 14 (7)
Any complication leading to severe maintained
hypotension
10 (5)
Any complication leading to the need of
haemodynamic support
7 (3)
Successful procedure 205 (96)
Lowest haemoglobin (g/dL) 9.8+1.5
Blood transfusion 104 (49)
Number of units 3.6+4.3
N-Acetylcysteine/bicarbonate pre-treatment 28 (13)
Post-procedural complications
Myocardial infarction 7 (3)
Stroke 7 (3)
Pneumonia/sepsis 21 (10)
Death 21 (10)
Continued
................................................................................
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Table 1 Continued
Variable n 5 213
Hospitalization length (days), median (interquartile
range)
6 (3–113)
Post-procedural renal impact
Serum creatinine at 48 h (mg/dL) 1.23+0.6
eGFR at 48 h (mL/min/1.73 m
2), median
(interquartile range)
60 (42–83)
eGFR changes at 48 h
No change in eGFR 2 (1)
Decrease in eGFR
  25% 61 (29)
. 25% 22 (10)
Increase in eGFR 128 (60)
% of increase in eGFR 26+19
Need for haemodialysis 3 (1)
Acute kidney injury 25 (12)
Values are expressed as n (%) or mean+SD unless otherwise noted.
eGFR, estimated glomerular ﬁltration rate.
TAVI and acute kidney injury 867The independent predictors of AKI following the procedure are
shown in Table 3.
Acute kidney injury and hospital
mortality
Hospital mortality occurred in 21 patients (9.8%). In those patients
presenting AKI, the mortality rate was 28% compared with 7.4% in
those patients with no AKI (P ¼ 0.005; P , 0.0001 after including
in the analysis the eight patients who died within the 24 h following
the procedure and for which post-procedural creatinine value
could not be assessed). Table 4 shows the clinical and peri-
procedural characteristics of the patients who died in the post-
operative period compared with those who survived. Patients
who died had more frequently a history of chronic obstructive pul-
monary disease (52 vs. 30%, P ¼ 0.049), had a higher logistic Euro-
SCORE (40.5+21.3 vs. 28.1+16.7%, P ¼ 0.001) and exhibited
higher levels of pulmonary artery systolic pressure (56+14 vs.
50+12 mmHg, P ¼ 0.033). The independent predictive factors
of hospital mortality are shown in Table 5.
Acute kidney injury in transcatheter
aortic valve implantation vs. surgical
aortic valve replacement procedures
The clinical and procedural characteristics of patients with pre-
procedural CKD grouped according to the type of procedure
(TAVI vs. SAVR) are shown in Table 6. Compared with patients
with CKD who underwent SAVR, patients with CKD who under-
went TAVI were older (83+7 vs. 74+8 years, P , 0.0001), and
presented more co-morbidities leading to a higher risk clinical
proﬁle (logistic EuroSCORE: 31.2+18.1 vs. 21.8+14.6%, P ,
0.0001). Also, baseline creatinine and eGFR values were higher
and lower, respectively, in TAVI patients compared with SAVR
patients (P , 0.0001 for both). Postoperative AKI occurred less
frequently in the TAVI group compared with the SAVR group
(9.2 vs. 25.9%, OR: 0.29, 95% CI: 0.14–0.62, P ¼ 0.001; OR:
0.33, 95% CI: 0.13–0.79, P ¼ 0.014 after propensity score
.............................................
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Table 2 Baseline and peri-procedural characteristics
of patients undergoing transcatheter aortic valve
implantation, according to the occurrence of
post-procedural acute kidney injury
Variable Acute kidney injury
Yes
(n 5 25)
No
(n 5 188)
P-value
Clinical characteristics
Age (years) 84+78 2 +8 0.129
Male sex 13 (52) 86 (46) 0.671
Diabetes 7 (28) 41 (22) 0.456
Hypertension 23 (92) 127 (68) 0.010
Congestive heart failure 15 (60) 100 (53) 0.670
New York Heart
Association class
I–II 4 (16) 18 (10)
III–IV 21 (84) 170 (90)
0.302*
Coronary artery disease 14 (56) 129 (69) 0.352
Cerebrovascular disease 6 (24) 55 (29) 0.647
Peripheral vascular disease 12 (48) 72 (38) 0.388
Chronic obstructive
pulmonary disease
13 (52) 56 (30) 0.038
Serum creatinine (mg/dL) 1.17+0.5 1.25+0.54 0.442
eGFR (mL/min/1.73 m
2),
median (interquartile
range)
70 (49–80) 57 (43–76) 0.252
eGFR ,60 (mL/min/
1.73 m
2)
11 (44) 108 (57) 0.284
Haemoglobin (g/dL) 12+1.7 12+1.5 0.547
Logistic EuroSCORE 34.3+21.8 28.7+16.8 0.131
Echocardiographic data
Left ventricular ejection
fraction
54+14 57+15 0.468
Left ventricular ejection
fraction ,40%
3 (13) 22 (12) 1.000
Mean gradient (mmHg) 41+14 44+17 0.319
Aortic valve area (cm
2) 0.62+0.11 0.63+0.17 0.884
Pulmonary artery systolic
pressure (mmHg)
54+17 50+12 0.231
Moderate to severe mitral
regurgitation
10 (44) 62 (34) 0.360
Peri-procedural variables
Approach
Transapical 16 (64) 86 (46)
0.093**
Transfemoral 9 (36) 102 (54)
Time of procedure (min),
median (interquartile
range)
104 (70–
160)
85 (74–
101)
0.153
Contrast amount (cm
3)7 9 +55 99+57 0.190
Rapid pacing runs 5.9+3.3 5.3+1.9 0.293
Life-threatening arrhythmias 3 (12) 11 (6) 0.217
Any complication leading to
severe maintained
hypotension
2 (8) 8 (4) 0.332
Continued
Figure 1 Changes in estimated glomerular ﬁltration rate
(eGFR) at 48 h following transcatheter aortic valve implantation
(TAVI).
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during index hospitalization in the TAVI and SAVR groups, respect-
ively (P ¼ 0.070). The differences remained signiﬁcant (TAVI: 9.4%
vs. SAVR: 28.1%; OR: 0.26, 95% CI: 0.10–0.72, P ¼ 0.011) after
patient matching on the basis of pre-procedural eGFR values (64
patients per group, mean eGFR: 49+8 mL/min). The changes in
eGFR following the procedure and grouped according to the
type of intervention (TAVI vs. SAVR) are shown in Figure 2.
Discussion
Acute kidney injury occurred in 11.7% of the patients following
TAVI, with 1.4% of them requiring dialysis. A history of hyperten-
sion, chronic obstructive pulmonary disease, and peri-operative
blood transfusion were predictive factors of AKI. Patients who pre-
sented AKI had a hospital mortality of 28%, and the occurrence of
AKI was an independent predictor of mortality, with greater than
four-fold increase in the risk of postoperative death among those
patients presenting AKI after TAVI. In patients with severe sympto-
matic AS and pre-procedural CKD, the incidence of AKI was lower
in those who underwent TAVI compared with those who under-
went SAVR (9.2 vs. 25.9%), despite the fact that TAVI patients
exhibited worse clinical risk proﬁle and poorer pre-procedural
kidney function.
Aregger et al.
9 evaluated the occurrence of AKI in a series of 54
patients who had undergone TAVI. Similarly to our results, most
patients (56%) increased eGFR values after TAVI, but the incidence
of AKI was 28% with up to 7.4% of the patients requiring dialysis
during index hospitalization. Compared with our study, creatinine
levels were determined daily during the hospitalization period,
baseline eGFR values were lower (mean: 55+26 mL/min/
1.73 m
2) and the amount of contrast media used during the pro-
cedure was higher (mean .200 cc). All these factors might have
contributed to the higher rate of AKI following TAVI in that
study. The presence of hypertension has been associated with
impaired kidney autoregulation which increases the risk of AKI
despite maintaining mean arterial pressure within the normal
range.
13 Hsu et al.
14 reported that hypertension increased the
risk of nosocomial AKI in patients with CKD. Also, hypertension
was shown to be an independent predictor of AKI following cardi-
othoracic surgery and percutaneous coronary intervention.
15,16
Chronic obstructive pulmonary disease has been shown to be an
independent predictor of AKI in patients undergoing cardiac
surgery,
1,17 and the present study also demonstrated that this
comorbidity increased the risk of AKI following TAVI by greater
than two-fold. Anand et al.
18 reported that patients with chronic
obstructive pulmonary disease may experience a signiﬁcant
reduction in renal blood ﬂow and glomerular ﬁltration. Also,
chronic obstructive pulmonary disease patients are more prone
to the occurrence of episodes of severe hypoxemia–hypercapnia
during the peri-operative period and this might indeed have con-
tributed to further deterioration of renal function.
19 The need for
RBC transfusion is avery well recognized predictorof AKI following
cardiac surgery.
4,20 Consistent with our results, Aregger et al.
9
recently showed that the number of blood transfusions was also
associated with an increased risk of AKI following TAVI. Preserved
RBCs undergo progressive functional and structuralchanges leading
to a reduction in RBC function and viability, and accumulate proin-
ﬂammatory molecules, free iron, and haemoglobin, and all these
changes might favour renal dysfunction, particularly in older
patients with impairment of kidney autoregulation.
20,21 The
present study showed that up to half of the patients undergoing
TAVI had received RBC transfusion and that this was associated
.............................................
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Table 2 Continued
Variable Acute kidney injury
Yes
(n 5 25)
No
(n 5 188)
P-value
Any complication leading to
the need of
haemodynamic support
2 (8) 5 (3) 0.192
Successful procedure 24 (96) 181 (96) 1.000
Lowest haemoglobin (g/dL) 9.9+1.5 9.8+1.5 0.892
Blood transfusion 19 (76) 85 (45) 0.005
Number of red cell blood
units
4.8+7.4 3.3+3.2 0.379
N-Acetylcysteine/
bicarbonate
pre-treatment
1 (4) 27 (14) 0.480
Post-procedural
complications
Myocardial infarction 2 (8) 5 (3) 0.192
Stroke 1 (4) 6 (3) 0.588
Pneumonia/sepsis 2 (8) 19 (10) 1.000
Death 7 (28) 14 (7) 0.005
Hospitalization length (days)
median (interquartile
range)
9 (5–30) 6 (4–10) 0.017
Post-procedural renal impact
Serum creatinine at 48 h
(mg/dL)
1.86+0.66 1.44+0.51 ,0.0001
eGFR at 48 h (mL/min/
1.73 m
2), median
(interquartile range)
36 (23–45) 64 (47–87) ,0.0001
Need for haemodialysis 3 (12) 0 0.001
Values are expressed as n (%) or mean+SD unless otherwise noted.
eGFR, estimated glomerular ﬁltration rate.
*P-value corresponds to both sets of variables, I–II and III–IV.
**P-value corresponds to both sets of variables, Transapical and Transfemoral.
................................................................................
Table 3 Independent predictors of acute kidney injury
following transcatheter aortic valve implantation
Variable Odds ratio (95%
CI)
P-value
Hypertension 4.66 (1.04–20.87) 0.044
Chronic obstructive pulmonary
disease
2.64 (1.10–6.36) 0.030
Red blood cell transfusion 3.47 (1.30–9.29) 0.013
TAVI and acute kidney injury 869....................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 4 Baseline and peri-procedural characteristics, and post-procedural renal impact of patients undergoing
transcatheter aortic valve implantation, according to the occurrence of hospital mortality
Variable In-hospital death
Yes (n 5 21) No (n 5 192) P-value
Clinical characteristics
Age (years) 82+10 82+8 0.873
Male, n (%) 14 (67) 85 (44) 0.065
Diabetes 3 (14) 45 (23) 0.421
Hypertension 15 (71) 135 (70) 1.000
Congestive heart failure 11 (52) 104 (54) 1.000
New York Heart Association class
I–II 2 (9) 20 (10)
1.000*
III–IV 19 (91) 172 (90)
Coronary artery disease 13 (62) 130 (68) 0.633
Cerebrovascular disease 9 (42) 52 (27) 0.135
Peripheral vascular disease 12 (57) 72 (38) 0.100
Chronic obstructive pulmonary disease 11 (52) 58 (30) 0.049
Serum creatinine (mg/dL) 1.41+0.67 1.23+0.52 0.136
eGFR (mL/min/1.72 m
2), median (interquartile range) 54 (36–74) 57 (43–77) 0.693
eGFR ,60 (mL/min/1.72 m
2) 12 (57) 107 (56) 1.000
Haemoglobin (g/dL) 11.7+1.4 12.0+1.6 0.320
Logistic EuroSCORE 40.5+21.3 28.1+16.7 0.001
Echocardiographic data
Left ventricular ejection fraction 52+15 60+15 0.193
Left ventricular ejection fraction ,40% 3 (16) 22 (12) 0.708
Mean gradient (mmHg) 37+13 45+17 0.044
Aortic valve area (cm
2) 0.65+0.15 0.62+0.16 0.497
Pulmonary artery systolic pressure (mmHg) 56+14 50+12 0.034
Moderate to severe mitral regurgitation 8 (42) 64 (34) 0.461
Peri-procedural variables
Approach
Transapical 14 (67) 88 (46) 0.106
Transfemoral 7 (33) 104 (54)
Time of procedure (min) median (interquartile range) 90 (69–110) 85 (74–105) 0.756
Contrast amount (cm
3)7 4 +59 99+57 0.148
Rapid pacing runs 5.5+2.0 5.4+2.2 0.876
Life-threatening arrhythmias 2 (10) 12 (6) 0.634
Any complication leading to severe maintained hypotension 2 (10) 8 (4) 0.257
Any complication leading to need haemodynamic support 1 (5) 6 (3) 0.522
Successful procedure 21 (100) 184 (96) 1.000
Lowest haemoglobin (g/dL) 9.6+1.7 9.9+1.5 0.528
Blood transfusion 14 (67) 90 (47) 0.108
Number of red blood cell units 6.6+8.1 3.1+3.1 0.137
N-Acetylcysteine/bicarbonate pre-treatment 4 (19) 24 (13) 0.443
Post-procedural complications
Myocardial infarction 1 (5) 6 (3) 0.521
Stroke 2 (10) 5 (3) 0.144
Pneumonia/sepsis 5 (24) 16 (8) 0.041
Post-procedural renal impact
Serum creatinine at 48 h (mg/dL) 1.54+0.71 1.19+0.55 0.008
eGFR at 48 h (mL/min/1.73 m
2), median (interquartile range) 45 (30–71) 60 (43–83) 0.080
Continued
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suggests that efforts should be made to avoid unnecessary blood
transfusions in patients undergoing TAVI.
Interestingly, the amount of contrast media was not associated
with AKI following TAVI. A contrast volume .100 cc has been
associated with contrast-induced nephropathy following percuta-
neous coronary intervention.
22–24 The fact that the mean contrast
volume used in the present study was ,100 cc might partially
explain the lack of correlation. Nonetheless, continued efforts to
minimize the amount of contrast media in these procedures (con-
trast dilution, contrast hand injections, and echocardiography
guiding for valve positioning
25) would be important to further
reduce the risk of AKI following TAVI. Finally, we found no corre-
lation between the number of rapid pacing runs and the occur-
rence of AKI, and this suggests that the short periods of severe
hypotension induced by rapid pacing do not play an important
role in the deterioration of renal function following TAVI.
However, the fact that the rapid pacing technique was used in all
patients limits our ability to completely rule out a potential role
for such short periods of hypotension in AKI following TAVI.
Acute kidney injury and hospital
mortality
Several studies have shown AKI to be a powerful predictor of
death at short-, mid-, and long-term follow-up after
cardiothoracic surgery and percutaneous coronary interven-
tion.
1–4,24 The present study is the ﬁrst to demonstrate that
AKI is associated with a higher (four-fold) postoperative mortality
following TAVI and that this association was independent of base-
line risk proﬁle characteristics and peri-procedural complications.
The pathophysiology explaining the prognostic role of AKI in the
early postoperative period of TAVI remains unclear. Although
AKI could have been only a marker of multisystem failure, our
results showed that the high mortality rate in patients with AKI
cannot be fully attributed to comorbidities or peri-procedural
complications, which suggests that AKI contributes directly to
early postoperative mortality. These results highlight the clinical
relevance of assessing kidney function within the 48 h following
TAVI in order to identify those patients who complicate with
AKI and thereby require close follow-up during the post-
procedural period.
Surgical aortic valve replacement vs.
transcatheter aortic valve implantation
in patients with pre-procedure chronic
kidney disease
Patients with preoperative CKD undergoing cardiac surgery are
at high risk of AKI and dialysis following the operation.
1
Gummert et al.
26 showed that up to 16% of the patients with
CKD undergoing SAVR required haemodialysis during the post-
operative period. The results of the present study showed that
in patients with previous renal dysfunction, the occurrence of
AKI was lower with TAVI (9.2%) compared with SAVR (25.9%).
Also, TAVI was associated with a non-signiﬁcant reduction in
the need for haemodialysis following the intervention compared
with SAVR. Interestingly, eGFR improved in most CKD patients
undergoing TAVI compared with less than half of the patients
undergoing SAVR. The deleterious effects of cardiopulmonary
bypass on renal function are well known
4,27 and its avoidance
would probably explain the better response in kidney function
....................................................................................
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Table 4 Continued
Variable In-hospital death
Yes (n 5 21) No (n 5 192) P-value
eGFR changes at 48 h
No change in eGFR 0 2 (1)
0.055**
Decrease in eGFR
  25% 4 (19) 57 (30)
. 25% 6 (29) 16 (8)
Increase in eGFR 11 (52) 117 (61)
% of increase in eGFR 22+10 27+20 0.199
Need for haemodialysis 1 (5) 2 (1) 0.269
Acute Kidney Injury 7 (33) 18 (9) 0.005
Values are expressed as n (%) or mean+SD unless otherwise noted.
eGFR, estimated glomerular ﬁltration rate.
*P-value corresponds to both sets of variables, I–II and III–IV.
**P-value corresponds to all sets of variables, No change in eGFR, Decrease in eGFR,  25%, .25%, and Increase in eGFR.
................................................................................
Table 5 Independent predictors of hospital mortality
following transcatheter aortic valve implantation
Variable Odds ratio (95% CI) P-value
Acute kidney injury 4.14 (1.42–12.13) 0.010
Logistic EuroSCORE 1.03
a (1.01–1.06) 0.009
aFor each increase of 1%.
TAVI and acute kidney injury 871obtained with TAVI in the high-risk subset of CKD patients with
severe AS. Future prospective randomized studies such as the
Placement of AoRTic TraNscathetER Valve (PARTNER) trial
should conﬁrm these results and determine whether the sole
presence of CKD should be used as a criterion to select TAVI
rather than SAVR in patients with symptomatic severe AS.
Study limitations
The results of this study were obtained from a database with
prospectively gathered data. However, this was a post hoc
non-pre-speciﬁed analysis and we cannot rule out the possibility
that other potential confounding variables not included in the
model might have affected the results. Also, the results were
based on a single determination of eGFR at 48 h following the pro-
cedure. We cannot exclude the possibility that further measure-
ments of creatinine levels during the hospitalization period might
have revealed a higher incidence of AKI. Due to the non-
randomized nature of the study, differences in the occurrence of
AKI between TAVI and SAVR should be seen as hypothesis gener-
ating and will need to be conﬁrmed by prospective randomized
studies. Finally, these results may not apply to lower volume
centres, especially at the beginning of the learning curve.
...............................................................................................................................................................................
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Table 6 Baseline characteristics and post-procedural renal impact in patients with chronic kidney disease, according to
the type (transcatheter vs. surgical) of treatment
Variable TAVI (n 5 119) SAVR (n 5 104) P-value
Clinical characteristics
Age (years) 83+77 4 +8 ,0.0001
Female gender 70 (59) 54 (52) 0.345
Diabetes 32 (27) 42 (40) 0.046
Hypertension 91 (77) 80 (77) 1.000
Congestive heart failure 66 (55) 16 (15) ,0.0001
Coronary artery disease 83 (70) 19 (18) ,0.0001
Cerebrovascular disease 37 (31) 12 (12) ,0.0001
Peripheral vascular disease 48 (40) 12 (12) ,0.0001
Chronic obstructive pulmonary disease 30 (25) 23 (22) 0.218
Serum creatinine (mg/dL) 1.54+0.54 1.35+0.28 ,0.0001
eGFR (mL/min/1.73 m
2), median (interquartile range) 46 (35–52) 50 (43–55) 0.0002
eGFR ,30 (mL/min/1.73 m
2) 20 (17) 1 (1) ,0.0001
Haemoglobin (g/dL) 11.8+1.5 12.4+1.6 0.002
Logistic EuroSCORE 31.2+18.1 21.8+14.6 ,0.0001
Echocardiographic data
Left ventricular ejection fraction 56+15 55+16 0.616
Left ventricular ejection fraction ,40% 16 (14) 15 (15) 0.848
Mean gradient (mmHg) 42+16 48+18 0.010
Aortic valve area (cm
2) 0.64+0.15 0.65+0.15 0.620
Pulmonary artery systolic pressure (mmHg) 51+13 44+17 0.023
Moderate to severe mitral regurgitation 46 (39) 6 (9) ,0.0001
Post-procedural renal impact
Serum creatinine at 48 h (mg/dL) 1.48+0.59 1.52+0.58 0.678
eGFR at 48 h (mL/min/1.73 m
2), median (interquartile range) 47 (30–60) 47 (34–38) 0.899
eGFR changes at 48 h
No changes in eGFR 2 (2) 1 (1)
0.005*
Decrease in eGFR
 25% 35 (29) 35 (34)
.25% 8 (7) 25 (24)
Increase in eGFR 74 (62) 43 (41)
% of increase in eGFR 28+21 22+26 0.174
Need for haemodialysis 3 (3) 9 (9) 0.071
Acute kidney injury 11 (9) 27 (26) 0.001
Values are expressed as n (%) or mean+SD unless otherwise noted.
TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; eGFR, estimated glomerular ﬁltration rate.
*P-value corresponds to all sets of variables, No change in eGFR, Decrease in eGFR,  25%, .25%, and Increase in eGFR.
R. Bagur et al. 872Conclusions
Acute kidney injury occurred in only 11.7% of the patients under-
going TAVI despite advanced age (mean .80 years) and the very
high-risk clinical proﬁle of the study population. Nonetheless, AKI
was a very powerful predictor of death during the postoperative
period independently of baseline comorbidities and peri-
procedural complications, and this highlights the importance of
both preventing and identifying such a complication early after
TAVI. Patients with hypertension and chronic obstructive pulmon-
ary disease and those receiving RBC transfusions were at higher
risk, suggesting that a more careful monitoring of patients with
these risk factors and a more restrictive strategy regarding blood
transfusion during TAVI might be clinically relevant. Finally, in the
high-risk group of patients with advanced age, symptomatic
severe AS, and pre-procedural chronic kidney disease, TAVI was
associated with greater than two-fold lower incidence of post-
operative AKI compared with SAVR. Future randomized studies
are needed to conﬁrm these results and determine whether
their prognostic relevance should lead to the favouring of TAVI
in this particular subset of patients.
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Dr Franz Messerli is nominated for the 2010 William
Harvey Award of the American Society of Hypertension
Franz H. Messerli, MD, FACC, FACP, originally from Switzerland and now Professor of Clinical Medi-
cine at Columbia University College of Physicians and Surgeons in New York, has been honoured as a
nominee for the William Harvey Award in 2010, in recognition of his pioneering work and accom-
plishments in hypertension. Starting in Jacque Genet’s cardiovascular laboratory in Montreal, then at
The Ochsner Medical Institution in New Orleans, Messerli has a long track record of signiﬁcant con-
tributions and developments to hypertension.
He has characterized and deﬁned the haemodynamics of hypertension, showing the biophysical
and biological interactions between cardiac output (CO) and systemic vascular resistance (SVR) in
producing the level of blood pressure (BP).
Messerli has performed outstanding work in the last several decades on a number of physiological, pathological, and pharmacologi-
cal areas in systemic hypertension. He showed the inverse relationship between CO and SVR as we advance in age, which has become
fundamental to our current understanding of the haemodynamics of BP control, and how ageing inﬂuences the level of BP. Franz’s
eloquent analysis and meta-analysis of b-blocker therapy for hypertension shed much light on this important treatment and
brought to our attention that chronic b-blocker therapy may induce diabetes in some patients. He also showed that it is necessary
to reduce heart rate as well as BP to provide a cardiovascular protection effect.
Franz’s life and work tells us to accept nothing secondhand, challenge accepted ideas, and aim our aspirations high. We should be
able to reject the narrow minded and status quo, yet recognize and respect the best of the past—with an eye to the future, so that we
change the scope of scientiﬁc thought.
In November 2009, he received The Franz-Gross-Science Prize from the German Hypertension League/Society, awarded once a
year to the most outstanding researcher in the ﬁeld of hypertension.
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